Minerva Neurosciences, Inc.
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system diseases. Its lead candidate, roluperidone, is in development for negative symptoms in patients with schizophrenia. The company is pursuing a Phase 3 confirmatory trial intended to support resubmission of its application to the FDA. It is also exploring other potential uses for roluperidone, including apathy in dementia, Alzheimer’s disease, Parkinson’s disease and depression. Minerva previously co-developed seltorexant with Janssen for insomnia and as an adjunctive treatment for major depressive disorder. In 2021, it sold its rights to potential royalties on seltorexant to Royalty Pharma. Minerva has not received regulatory approval to commercialize its product candidates and has not generated revenue from their sales or licenses. It is headquartered in Burlington, Massachusetts.
No SEC Form 4 filings for $NERV in the last 30 days.
See all $NERV insider activity →Minerva Neurosciences reported Q3 GAAP EPS of -$0.19, missing estimates by $0.01. Cash and equivalents were $77.0M on Sept 30, 2026, down from $82.4M on Dec 31, 2025, according to the company.
Minerva Neurosciences reported Q3 2026 GAAP net income of $100.7M, driven by a $109.6M non-cash gain. Adjusted net loss was $5.6M. Cash reserves totaled $77.0M. R&D and G&A expenses increased year-over-year. The company's Phase 3 C19 study for roluperidone is ongoing, with data expected in 2027 and 2028.
Minerva Neurosciences, Inc. (NERV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic s
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning NERV (Minerva Neurosciences, Inc.). Coverage has been balanced: 1 bullish, 3 neutral, and 1 bearish.
Recent NERV coverage spans earnings, financial news and corporate actions.
Earnings miss suggests weaker performance than anticipated.
Strong GAAP profit surprise may lift the stock.
Quarterly earnings surprise with large non‑cash gain may cause short‑term volatility.
This is a corporate governance and finance-control change, with modest compensation details, likely low immediate impact but relevant for accounting oversight and internal controls.
The article reinforces the clinical execution timeline for roluperidone’s confirmatory Phase 3, a key catalyst for valuation and risk.
AlphAI scores every news story that mentions NERV with an AI model for sentiment and relevance, and aggregates insider trades from Minerva Neurosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Minerva Neurosciences reported Q3 GAAP EPS of -$0.19, missing estimates by $0.01. Cash and equivalents were $77.0M on Sept 30, 2026, down from $82.4M on Dec 31, 2025, according to the company.
Minerva Neurosciences reported Q3 2026 GAAP net income of $100.7M, driven by a $109.6M non-cash gain. Adjusted net loss was $5.6M. Cash reserves totaled $77.0M. R&D and G&A expenses increased year-over-year. The company's Phase 3 C19 study for roluperidone is ongoing, with data expected in 2027 and 2028.
Minerva Neurosciences, Inc. (NERV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Recent Schizophrenia Research article describes need to expand basic s
Minerva Neurosciences, Inc. (NERV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 10, 2026, the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) appointed Anthony A
Minerva Neurosciences (Nasdaq: NERV) reported Q2 2026 results and updates. Its confirmatory Phase 3 trial of roluperidone (MIN-101C19) for schizophrenia negative symptoms is ongoing, with topline efficacy expected in 2H 2027. R&D rose to $7.2M in Q2 2026 from $1.3M. GAAP net income was $17.5M, driven by a $27.6M non-cash warrant gain.
Minerva Neurosciences, Inc. (NERV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuros
Wall Street Zen upgraded Minerva Neurosciences (NASDAQ:NERV) from "sell" to "hold," although the consensus rating on MarketBeat remains "Reduce." The company reported a quarterly EPS of -$0.36, missing estimates, and institutional ownership stands at approximately 34.56%. The stock's current market cap is $169.62 million with a P/E ratio of -2.12.
Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
Minerva Neurosciences Inc ( NASDAQ:NERV ) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia ...
